Expanded roles of the renin-angiotensin system

Hypertension Research

Volumn 36, Issue 7, 2013, Pages 586-587

  Fukuda, Daiju ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RENIN INHIBITOR; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG SUBSTITUTION; FIBRINOLYSIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; NOTE; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIPHENYL COMPOUNDS; FEMALE; HUMANS; HYPERTENSION; MALE; TETRAZOLES;

EID: 84881412061     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.27     Document Type: Note

References (10)

1. Fukuda D, Sata M, Ishizaka N, Nagai R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90-96.
2. Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007; 30: 1119-1128.
3. Mogi M, Iwai M, Horiuchi M. Emerging concept of adipogenesis regulation by the renin-angiotensin system. Hypertension 2006; 48: 1020-1022. (Pubitemid 44772700)
4. Kalupahana NS, Massiera F, Quignard-Boulange A, Ailhaud G, Voy BH, Wasserman DH, Moustaid-Moussa N. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2012; 20: 48-56.
5. Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C, Higashida M, Mikasa H, Nakaya Y, Takanashi S, Igarashi T, Kitagawa T, Sata M. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248-255.
6. Fujimura A, Ushijima K, Ando H. Does the PPAR-g-activating property of telmisartan provide a benefit in clinical practice? Hypertens Res 2012; 36: 183.
7. Nakagami H, Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-g. Curr Vasc Pharmacol 2011; 9: 162-166.
8. Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens Res 2013; 36: 608-613.
9. Fukuda D, Enomoto S, Hirata Y, Nagai R, Sata M. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. Biomed Pharmacother 2010; 64: 712-717.
10. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, Hirata Y, Kurobe H, Sakaue H, Nakaya Y, Masuzaki H, Sata M. Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: a possible link to anti-metabolic effects. Eur J Pharmacol 2012; 692: 84-90.